Several PPAR agonists were/are used as medications (e.g., the triglyceride-lowering fibrates and the antidiabetic pioglitazone) or are being developed as next-generation therapeutics for metabolic diseases such as type 2 diabetes, dyslipidemia, and metabolic dysfunction-associated fatty liver disease, chronic inflammatory disease, cardiovascular disease, autoimmune disease, neurodegenerative disease, and cancer [2,3,4,5,6]. Here, PPARA is linked to autoimmune disease.